Equities analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to report earnings of ($0.90) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Blueprint Medicines Corp’s earnings, with estimates ranging from ($0.92) to ($0.85). Blueprint Medicines Corp posted earnings of ($0.62) per share during the same quarter last year, which would indicate a negative year over year growth rate of 45.2%. The business is scheduled to report its next earnings report on Thursday, November 9th.

According to Zacks, analysts expect that Blueprint Medicines Corp will report full year earnings of ($3.57) per share for the current year, with EPS estimates ranging from ($3.69) to ($3.47). For the next year, analysts anticipate that the firm will post earnings of ($4.17) per share, with EPS estimates ranging from ($4.43) to ($3.95). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Blueprint Medicines Corp.

Blueprint Medicines Corp (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.11. The firm had revenue of $5.89 million for the quarter, compared to the consensus estimate of $5.96 million. Blueprint Medicines Corp had a negative return on equity of 47.67% and a negative net margin of 567.27%. The firm’s quarterly revenue was down 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.70) earnings per share.

BPMC has been the subject of a number of research analyst reports. BidaskClub raised Blueprint Medicines Corp from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Zacks Investment Research raised Blueprint Medicines Corp from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Canaccord Genuity set a $52.00 target price on Blueprint Medicines Corp and gave the company a “buy” rating in a research report on Tuesday, June 6th. Cowen and Company reaffirmed a “buy” rating on shares of Blueprint Medicines Corp in a research report on Tuesday, June 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Blueprint Medicines Corp in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $49.77.

In other Blueprint Medicines Corp news, insider Anthony L. Boral sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $48.60, for a total transaction of $243,000.00. Following the completion of the sale, the insider now directly owns 5,000 shares of the company’s stock, valued at approximately $243,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Lynch sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $55.06, for a total value of $412,950.00. Following the sale, the director now directly owns 211,842 shares of the company’s stock, valued at $11,664,020.52. The disclosure for this sale can be found here. Insiders have sold a total of 128,622 shares of company stock valued at $6,484,605 over the last three months. Corporate insiders own 3.40% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC increased its holdings in Blueprint Medicines Corp by 10.8% during the 2nd quarter. FMR LLC now owns 5,300,589 shares of the biotechnology company’s stock worth $268,581,000 after purchasing an additional 516,835 shares in the last quarter. Wellington Management Group LLP increased its holdings in Blueprint Medicines Corp by 200.4% during the 1st quarter. Wellington Management Group LLP now owns 3,821,584 shares of the biotechnology company’s stock worth $152,826,000 after purchasing an additional 2,549,623 shares in the last quarter. BlackRock Inc. increased its holdings in Blueprint Medicines Corp by 39.6% during the 2nd quarter. BlackRock Inc. now owns 2,864,255 shares of the biotechnology company’s stock worth $145,131,000 after purchasing an additional 811,820 shares in the last quarter. Lord Abbett & CO. LLC increased its holdings in Blueprint Medicines Corp by 0.5% during the 2nd quarter. Lord Abbett & CO. LLC now owns 1,729,169 shares of the biotechnology company’s stock worth $87,617,000 after purchasing an additional 8,903 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Blueprint Medicines Corp by 16.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock worth $71,746,000 after purchasing an additional 195,517 shares in the last quarter. 90.71% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/09/blueprint-medicines-corp-bpmc-expected-to-post-earnings-of-0-90-per-share.html.

Blueprint Medicines Corp (NASDAQ:BPMC) opened at 52.28 on Friday. The company’s 50 day moving average price is $50.44 and its 200-day moving average price is $44.63. Blueprint Medicines Corp has a 12-month low of $25.08 and a 12-month high of $56.93. The company’s market capitalization is $2.05 billion.

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Get a free copy of the Zacks research report on Blueprint Medicines Corp (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines Corp (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp and related companies with MarketBeat.com's FREE daily email newsletter.